nateglinide (Starlix)

Indications

• diabetes mellitus type 2
  • control of postprandial hyperglycemia

Dosage

60-120 mg TID before meals

Pharmacokinetics

• onset of action 15-30 minutes
• duration of action 2 hours

Mechanism of action

• stimulates insulin secretion by pancreatic islet beta cells
• D-phenylalanine derivative

Clinical trials

• Navigator study
  • nateglinide did not reduce the incidence of diabetes or cardiovascular complications

More general terms

• meglitinide (Meglitinido, Meglitinidum)

Database

• PubChem: http://pubchem.ncbi.nlm.nih.gov/summary/summary.cgi?cid=443871
• PubChem: http://pubchem.ncbi.nlm.nih.gov/summary/summary.cgi?cid=60026
• PubChem: http://pubchem.ncbi.nlm.nih.gov/summary/summary.cgi?cid=5311309
• PubChem: http://pubchem.ncbi.nlm.nih.gov/summary/summary.cgi?cid=4443